Top

Reactions Weekly

Published in:

01-06-2021 | Ribavirin | Case report

Ribavirin/sofosbuvir/velpatasvir

Virological failure and myositis: 5 case reports

Published in: Reactions Weekly | Issue 1/2021

Excerpt

Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

* death
* life-threatening
* hospitalisation
* disability
* congenital anomaly
* other medically important event

…

Identifying patient details (age and sex) of the patient, who developed myositis, have been obtained through direct communication with the author.

Wong YJ, et al. Efficacy and safety of sofosbuvir/velpatasvir in a real-world chronic hepatitis C genotype 3 cohort. Journal of Gastroenterology and Hepatology 36: 1300-1308, No. 5, May 2021. Available from: URL: http://doi.org/10.1111/jgh.15324

Title: Ribavirin/sofosbuvir/velpatasvir
Virological failure and myositis: 5 case reports
Publication date: 01-06-2021
Publisher: Springer International Publishing
Keywords: Ribavirin
Hepatitis C
Urosepticemia
Published in: Reactions Weekly / Issue 1/2021
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-021-97761-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Ribavirin/sofosbuvir/velpatasvir

Virological failure and myositis: 5 case reports

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2021

Chlordiazepoxide/clidinium-bromide/dipotassium-clorazepate/mebeverine

Multiple drugs

Fluoxetine/sertraline

Alemtuzumab/furosemide/glucocorticoids

Multiple drugs

Everolimus